Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer's disease mice

Neurobiology of Aging

Volumn 35, Issue 11, 2014, Pages 2458-2464

  Di Meco, Antonio ^a   Lauretti, Elisabetta ^a   Vagnozzi, Alana N ^a   Praticò, Domenico ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 Lipoxygenase; Alzheimer's disease; Amyloid beta; Memory; Tau protein; Transgenic mouse models

Indexed keywords

AMYLOID BETA PROTEIN; ARACHIDONATE 5 LIPOXYGENASE; CYCLIN DEPENDENT KINASE 5; GAMMA SECRETASE; PLACEBO; TAU PROTEIN; ZILEUTON; AMYLOID PROTEIN; CDK5 PROTEIN, MOUSE; HYDROXYUREA; LIPOXYGENASE INHIBITOR; PROTEIN AGGREGATE; SECRETASE;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; MEMORY DISORDER; MENTAL CAPACITY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; ANALOGS AND DERIVATIVES; ANIMAL; ENZYMOLOGY; MEMORY; METABOLISM; MOLECULARLY TARGETED THERAPY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN AGGREGATION, PATHOLOGICAL; PSYCHOLOGY; TRANSGENIC MOUSE; UPREGULATION;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; AMYLOIDOGENIC PROTEINS; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CYCLIN-DEPENDENT KINASE 5; HYDROXYUREA; LIPOXYGENASE INHIBITORS; MEMORY; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; TAU PROTEINS; UP-REGULATION;

EID: 84922129260     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.05.016     Document Type: Article

References (17)

1. Chinnici C.M., Yao Y., Praticò D. The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. Neurobiol. Aging 2007, 28:1457-1462.
2. Chu J., Li J.G., Ceballos-Diaz C., Golde T., Praticò D. The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: invivo and invitro evidence. Biol. Psychiatry 2013, 74:321-328.
3. Chu J., Li J.,G., Praticò D. Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles. PLoS One 2013, 8. e70991, 1-7.
4. Chu J., Praticò D. 5-lipoxygenase as an endogenous modulator of amyloid β formation invivo. Ann. Neurol. 2011, 69:34-46.
5. Cripps D., Thomas S.T., Jeng Y., Yang F., Davies P., Yang A.J. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J.Biol. Chem. 2006, 281:10825-10838.
6. Firuzi O., Zhuo J., Chinnici C.M., Wisniewski T., Praticò D. 5-Lipoxygenase gene disruption reduces amyloid-β pathology in a mouse model of Alzheimer's disease. FASEB J. 2008, 22:1169-1178.
7. Giannopoulos P.F., Chu J., Joshi Y.B., Sperow M., Li J.G., Kirby L.G., Pratico D. Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease. Mol. Psych 2014, 19:511-518.
8. Ikonomovic M.D., Abrahamson E.E., Uz T., Manev H., Dekosky S.T. Increased 5-lipooxygenase immunoreactivity in hippocampus of patients with Alzheimer' diseases. J.Histochem. Cytochem. 2008, 56:1065-1073.
9. Joshi Y.B., Praticò D. The involvement of 5-lipoxygenase activating protein in anxiety-like behavior. J.Psychiatr. Res. 2013, 47:694-698.
10. Martin L., Latypova X., Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem. Int. 2011, 58:458-471.
11. Oddo S., Vasilevko V., Caccamo A., Kitazawa M., Cribbs D.H., La Ferla F.M. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J.Biol. Chem. 2006, 281:39413-39423.
12. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular aβ and synaptic dysfunction. Neuron 2003, 39:409-421.
13. Querfurth H.W., La Ferla F.M. Alzheimer's disease. N.Engl. J. Med. 2010, 362:329-344.
14. Radmark O., Werz O., Steinhilber D., Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem. Sci. 2007, 32:332-341.
15. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek K., Ingelsson M., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
16. Wallin A.K., Blennow K., Andreasen N., Minthon L. CSF biomarkers for Alzheimer's disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement. Geriatr. Cogn. Disord. 2006, 21:131-138.
17. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease-a double-edge sword. Neuron 2002, 35:419-432.